<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959113</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD 131244.1</org_study_id>
    <nct_id>NCT01959113</nct_id>
  </id_info>
  <brief_title>Validation of the Short-term Antimicrobial Action of Transplanted Bacteria</brief_title>
  <official_title>Phase 1 Study of the Short-term Antimicrobial Action of Transplanted Bacteria in Adult Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently&#xD;
      colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of&#xD;
      S. aureus skin infections. In addition, research in the investigator's lab has shown that&#xD;
      these patients have fewer protective antimicrobial Staphylococcal species such as&#xD;
      Staphylococcal epidermidis (S. epidermidis) that are known to produce antimicrobial peptides&#xD;
      that play a role in protecting the skin from invading pathogens. In this study, the&#xD;
      investigator will attempt to decrease S. aureus colonization and increase colonization by&#xD;
      protective Staph species in AD patients. First the investigator will capture the bacteria on&#xD;
      subjects' lesional AD skin. Next the investigator will selectively grow the subject's&#xD;
      antimicrobial Staphylococcal colonies and place them into a base moisturizer. The moisturizer&#xD;
      plus bacteria will be applied to one of the subject's arms, and the moisturizer alone&#xD;
      (without bacteria) to the other arm. The investigator will then do a quantitative wash of the&#xD;
      bacteria growing on each arm one day later in order to determine whether the S. aureus&#xD;
      abundance was affected by the application of the transplanted bacteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Staphylococcus Aureus Abundance</measure>
    <time_frame>24-hours post-transplant</time_frame>
    <description>The technique of quantitative washes will be used to determine the Staphylococcus aureus abundance on an area of lesional AD skin on the subject's forearm as a ratio of baseline S. aureus abundance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Autologous Microbiome Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will have a base moisturizer alone applied to it during the third visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Microbiome Transplant</intervention_name>
    <arm_group_label>Autologous Microbiome Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Arm</intervention_name>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>The placebo arm will have a commercially available moisturizer applied to it.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects who are not pregnant or lactating&#xD;
&#xD;
          -  18-80 years of age&#xD;
&#xD;
          -  Diagnosis of atopic dermatitis for at least 6 months using the Hanifin and Rajka&#xD;
             Diagnostic Criteria for atopic dermatitis&#xD;
&#xD;
          -  Presence of lesional atopic dermatitis skin in both antecubital fossae&#xD;
&#xD;
          -  Positive methicillin-sensitive S. aureus colonization based on results of a skin&#xD;
             culture taken from one of their AD-affected antecubital fossae during the screening&#xD;
             visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any topical AD treatments (including topical steroids, topical calcineurin&#xD;
             inhibitors) to either arm within one week of either screening visit&#xD;
&#xD;
          -  Use of any oral/systemic AD therapies (antihistamines, steroids) within 28 days of&#xD;
             either screening visit&#xD;
&#xD;
          -  Severe AD that would worsen significantly from holding a participant's usual&#xD;
             topical/oral AD medications for the time periods required in the inclusion/exclusion&#xD;
             criteria (one week prior to the screening visits and during the study for topical&#xD;
             medications and 28 days prior to screening visits and during the study for oral&#xD;
             medications)&#xD;
&#xD;
          -  Subjects who have taken a bleach bath within a week prior to screening, or who take&#xD;
             bleach baths during the study&#xD;
&#xD;
          -  Patients with severe medical condition(s) that in the view of the investigator&#xD;
             prohibits participation in the study&#xD;
&#xD;
          -  Subjects with Netherton's syndrome or other genodermatoses that result in a defective&#xD;
             epidermal barrier&#xD;
&#xD;
          -  Any subject who is immunocompromised (e.g. provides researchers with a history&#xD;
             lymphoma, HIV/AIDS, Wiskott-Aldrich Syndrome) or has a history of malignant disease&#xD;
             (with the exception of non-melanomatous skin cancer). This information will be&#xD;
             gathered verbally from the patient while taking a medical history from the patient,&#xD;
             and will not involve further testing such as an HIV test.&#xD;
&#xD;
          -  Subjects with a history of psychiatric disease or history of alcohol or drug abuse&#xD;
             that would interfere with the ability to comply with the study protocol&#xD;
&#xD;
          -  Active bacterial, viral or fungal skin infections&#xD;
&#xD;
          -  Any noticeable breaks or cracks in the skin on either arm, including severely&#xD;
             excoriated skin or skin with open or weeping wounds suggestive of an active infection&#xD;
             or increased susceptibility to infection.&#xD;
&#xD;
          -  Ongoing participation in another investigational trial&#xD;
&#xD;
          -  Use of any oral or topical antibiotic for up to four weeks prior to screening&#xD;
&#xD;
          -  Use of any systemic immunosuppressive therapy (e.g. cyclosporin, methotrexate, etc.)&#xD;
             within four weeks of screening.&#xD;
&#xD;
          -  Sensitivity to or difficulty tolerating Dove fragrance-free bar soap, Dial&#xD;
             antibacterial liquid soap, Cetaphil lotion, or alcohol-based cleaners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Division of Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <results_first_submitted>May 13, 2020</results_first_submitted>
  <results_first_submitted_qc>June 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 17, 2020</results_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Richard Gallo</investigator_full_name>
    <investigator_title>Professor and Chair, Division of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Bacteria transplant</keyword>
  <keyword>Atopic dermatitis treatments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults with AD were recruited from the University of California, San Diego (UCSD), La Jolla, CA, and the National Jewish Health (NJH), Denver, CO.</recruitment_details>
      <pre_assignment_details>All subjects avoided any treatments and therapies that may potentially affect skin microbiome before sample collection.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Autologous Microbiome Transplant and Placebo (Split-design)</title>
          <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.&#xD;
Autologous Microbiome Transplant&#xD;
Placebo vehicle cream will be applied to the contralateral arm. This arm is the placebo arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>5 subjects with AD were enrolled in the study. Each of the subject's arms was randomly assigned to treatment with AMT or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Autologous Microbiome Transplant and Placebo (Split-design)</title>
          <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.&#xD;
Autologous Microbiome Transplant&#xD;
Placebo vehicle cream will be applied to the contralateral arm. This arm is the placebo arm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.8" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Staphylococcus Aureus Abundance</title>
        <description>The technique of quantitative washes will be used to determine the Staphylococcus aureus abundance on an area of lesional AD skin on the subject's forearm as a ratio of baseline S. aureus abundance</description>
        <time_frame>24-hours post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>This arm will have a base moisturizer alone applied to it during the third visit.&#xD;
Placebo Arm</description>
          </group>
          <group group_id="O2">
            <title>Autologous Microbiome Transplant</title>
            <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.&#xD;
Autologous Microbiome Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Staphylococcus Aureus Abundance</title>
          <description>The technique of quantitative washes will be used to determine the Staphylococcus aureus abundance on an area of lesional AD skin on the subject's forearm as a ratio of baseline S. aureus abundance</description>
          <units>ratio to baseline S. aureus abundance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>arms</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>arms</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.2"/>
                    <measurement group_id="O2" value="12.2" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after baseline visit</time_frame>
      <desc>Participants were asked about adverse events by phone 30 days after baseline visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Autologous Microbiome Transplant</title>
          <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.&#xD;
Autologous Microbiome Transplant</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Split-design)</title>
          <description>Placebo vehicle cream will be applied to the contralateral arm. This arm is the placebo arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials Unit</name_or_title>
      <organization>University of California, San Diego</organization>
      <phone>858-657-8390</phone>
      <email>dermstudies@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

